Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1089/jir.2020.0135 http://scihub22266oqcxt.onion/10.1089/jir.2020.0135 33621130!ä!33621130 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Interferon+Cytokine+Res 2021 ; 41 (2): 37-43 Nephropedia Template TP {{tp|p=33621130|t=2021. Perspectives on Targeting IL-6 as a Potential Therapeutic Strategy for COVID-19 |pdf=|usr=}}{{33621130}} gab.com Text Perspectives on Targeting IL-6 as a Potential Therapeutic Strategy for COVID-19 JO: J Interferon Cytokine Res http://www.kidney.de/pget.php?&tw=1&pmid=33621130 #FOAvip Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has been a major threat to global public health. In Indonesia, the cases have rapidly increased, and the case fatality rate remains high. With COVID-19, most of the deaths have been caused by acute respiratory distress syndrome and dysregulation of the immune response. A lung biopsy from a patient with COVID-19 showed inflammatory cellular infiltration with diffuse alveolar damage. Massive pulmonary destruction has also been reported as a result of highly increased levels of proinflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), IL-1beta, interferon-gamma (IFN-gamma), induced protein 10 (IP-10), and monocyte chemoattractant protein-1 (MCP-1). IL-6 is an inflammatory cytokine produced by various cell types, including immune cells and nonleukocytes, such as endothelial cells, fibroblasts, epithelial cells, type II pneumocytes, and certain tumor cells. Several studies have shown that IL-6 contributes to the severity and mortality of COVID-19. In this review, we would like to explore the immune response in COVID-19 and the role of IL-6 in the immunopathogenesis of COVID-19. Twit Text FOAVip Perspectives on Targeting IL-6 as a Potential Therapeutic Strategy for COVID-19 ????J Interferon Cytokine Res http://www.kidney.de/pget.php?&tw=1&pmid=33621130 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33621130 #FOAvip English Wikipedia <ref>{{Cite pmid|33621130}}</ref> Perspectives on Targeting IL-6 as a Potential Therapeutic Strategy for COVID-19 #MMPMID33621130 Khaedir Y; Kartika R J Interferon Cytokine Res 2021[Feb]; 41 (2): 37-43 PMID33621130show ga Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has been a major threat to global public health. In Indonesia, the cases have rapidly increased, and the case fatality rate remains high. With COVID-19, most of the deaths have been caused by acute respiratory distress syndrome and dysregulation of the immune response. A lung biopsy from a patient with COVID-19 showed inflammatory cellular infiltration with diffuse alveolar damage. Massive pulmonary destruction has also been reported as a result of highly increased levels of proinflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), IL-1beta, interferon-gamma (IFN-gamma), induced protein 10 (IP-10), and monocyte chemoattractant protein-1 (MCP-1). IL-6 is an inflammatory cytokine produced by various cell types, including immune cells and nonleukocytes, such as endothelial cells, fibroblasts, epithelial cells, type II pneumocytes, and certain tumor cells. Several studies have shown that IL-6 contributes to the severity and mortality of COVID-19. In this review, we would like to explore the immune response in COVID-19 and the role of IL-6 in the immunopathogenesis of COVID-19. |Antibodies, Monoclonal, Humanized/therapeutic use[MESH] |COVID-19 Drug Treatment[MESH] |COVID-19/*pathology[MESH] |Cytokine Release Syndrome/drug therapy/pathology/prevention & control[MESH] |Humans[MESH] |Indonesia[MESH] |Interleukin-6/immunology[MESH] |Janus Kinase 1/antagonists & inhibitors[MESH] |Janus Kinase 2/antagonists & inhibitors[MESH] |Janus Kinase Inhibitors/therapeutic use[MESH] |Nitriles[MESH] |Pyrazoles/therapeutic use[MESH] |Pyrimidines[MESH] |Receptors, Interleukin-6/*antagonists & inhibitors[MESH] |Respiratory Distress Syndrome/*drug therapy[MESH] |SARS-CoV-2/drug effects/*immunology[MESH]Perspectives on Targeting IL-6 as a Potential Therapeutic Strategy for(epmc).pdf DeepDyve Pubget Overpricing